## **ORIGINAL COMMUNICATION**



# **Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients**

 $\textsf{Stefania Nannoni}^1\textcolor{red}{\textcircled{{\bullet}}}$  $\textsf{Stefania Nannoni}^1\textcolor{red}{\textcircled{{\bullet}}}$  $\textsf{Stefania Nannoni}^1\textcolor{red}{\textcircled{{\bullet}}}$  · Gaia Sirimarco<sup>1</sup> · Carlo W. Cereda<sup>1,2</sup> · Dimitris Lambrou<sup>1</sup> · Davide Strambo<sup>1</sup> · **Ashraf Eskandari1 · Pascal J. Mosimann3 · Max Wintermark4 · Patrik Michel1**

Received: 15 November 2018 / Revised: 22 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

## **Abstract**

**Background** In acute ischemic stroke (AIS) collaterals correlate with infarct size, recanalization rate and clinical outcome. We aimed to identify factors associated with better collateral status in a large series of AIS patients with middle cerebral artery (MCA) occlusion.

**Methods** In the Acute STroke Registry and Analysis of Lausanne (ASTRAL) from 2003 to 2016, we identified all consecutive AIS with proximal MCA occlusion on CT-angiography performed<24 h. Collaterals were scored from 0 (absent) to  $3 (2100%)$  and related to multiple demographic, clinical, metabolic and radiological variables in a multivariate regression analysis (MVA).

**Results** The 857 included patients had a median age of 72.3 years, 48.4% were female and median admission NIHSS was 16. Better collaterals were associated with younger age (OR 0.99; 95% CI 0.98–1.00), hemineglect (OR 1.35; 95% CI 1.03–1.76), absence of visual field defects (OR 0.64; 95% CI 0.46–0.90), eye deviation (OR 0.58; 95% CI 0.43–0.79) and decreased vigilance (OR 0.62; 95% CI 0.44–0.88). Better collaterals were also associated with dyslipidemia (OR 1.57; 95% CI 1.16–2.13), no previous statin use (OR 0.69; 95% CI 0.50–0.95), and lower creatinine levels (OR 0.99; 95% CI 0.99–1.00). On neuroimaging, better collaterals related to higher ASPECTS score (OR 1.27; 95% CI 1.20–1.35) and higher clot burden score (OR 1.09; 95% CI 1.03–1.14).

**Conclusions** Younger age, dyslipidemia and lower creatinine levels were predictors of better collaterals in AIS patients from proximal MCA occlusions. Greater degree of collaterals related to lower stroke severity on admission. On neuroimaging, better collaterals were independently associated with minor early ischemic changes and lower clot burden. These data may add knowledge on pathophysiology of collaterals development and may help to identify patients with better collaterals for late or aggressive recanalization treatments.

**Keywords** Acute ischemic stroke · Collateral circulation · Computed tomography-angiography (CTA) · Acute neuroimaging

Preliminary results of our study have been presented on the International Stroke Conference 2017 in Houston (USA) as a poster. Definitive results have been presented as an oral communication on the European Stroke Organization Conference 2017, taking place in Prague (Czech Republic).

**Electronic supplementary material** The online version of this article [\(https://doi.org/10.1007/s00415-018-09170-3\)](https://doi.org/10.1007/s00415-018-09170-3) contains supplementary material, which is available to authorized users.

 $\boxtimes$  Stefania Nannoni Stefania.Nannoni@chuv.ch

Extended author information available on the last page of the article

## **Abbreviations**

- AIS Acute ischemic stroke
- CBS Clot burden score
- MCA Middle cerebral artery

# **Introduction**

Leptomeningeal arterial collaterals are pre-existing anastomoses that cross-connect a small number of distal arterioles of the cerebral arteries [\[1](#page-5-0)]. They provide alternative blood flow to support brain viability when a primary vessel in the cervico-cephalic arteries is critically stenosed or occluded, such as in acute ischemic stroke (AIS). A

greater degree of collaterals at baseline has been associated with smaller infarct size [[2](#page-5-1)], improved recanalization rate after endovascular treatment [\[3](#page-5-2)] and improved clinical outcome [[4](#page-5-3), [5\]](#page-5-4).

The magnitude of collateral flow varies greatly between patients. Still, studies examining determinants of this variability are lacking. Besides genetic and environmental factors, statin use has been associated with good collaterals [[6\]](#page-5-5), whereas a history of hypertension and higher systolic blood pressure on admission have been associated with poor collateral status at baseline [[7](#page-6-0)]. Recently, the presence of metabolic syndrome, hyperuricemia and aging were found as independent predictors of poor leptomeningeal collateral status [[8](#page-6-1)]. Malik et al. confirmed the association between poor collaterals and older age, but did not find a favourable influence of pre-stroke statin use on the patency of collateral circulation [\[9](#page-6-2)].

The main aim of our study was to investigate factors associated with the degree of leptomeningeal collateral status in a large cohort of AIS patients. In particular, we performed a comprehensive analysis of a large number of possibly associated variables, including demographic, clinical, biochemical, and radiological variables, to identify independent predictors of better collaterals in the acute phase of stroke.

## **Methods**

## **Patient selection**

All consecutive patients included in the Acute STroke Registry and Analysis of Lausanne (ASTRAL) from January 2003 to June 2016 were considered for this study. ASTRAL is a single-center prospective cohort of all AIS patients admitted to the Stroke Center of Lausanne University Hospital within 24 h of an ischemic stroke [[10](#page-6-3)]. It incorporates detailed clinical and laboratory data and multimodal brain imaging techniques. The type and definition of collected variables in ASTRAL is prespecified, and the current analysis was retrospective.

For patient selection, we used the following inclusion criteria: AIS involving the middle cerebral artery (MCA); CTbased multimodal imaging performed<24 h of last proof of good health; availability of a CT-angiography (CTA) of good quality showing occlusion of the proximal segments (M1 and/or proximal M2), with or without added more distal and more proximal (carotid siphon, extracranial carotid artery) pathology. Patients with only distal M2 or only M3 occlusions were excluded because visual assessment of collaterals in a small arterial territory was considered insufficiently reliable.

#### **Clinical variables**

Demographic data (age and gender), medical history and vascular risk factors (such as previous cerebrovascular events, arterial hypertension, diabetes mellitus, dyslipidemia, smoking, and atrial fibrillation) were recorded. We collected pre-stroke modified Rankin scale (mRs) and current medications at the time of stroke. We recorded "new neurological deficits", that are new (i.e. not preexisting), focal neurological deficits, such as visual field defects, eye deviation, aphasia, neglect and vigilance impairment, assessed by a neurologist during the initial evaluation of a patient with suspected acute ischemic stroke, as noted in the medical records. Stroke severity was scored by National Institutes of Health Stroke Scale (NIHSS). We measured vital signs (body temperature, and blood pressure), metabolic and hematologic parameters at admission and calculated onset-to-door, onset-to brain imaging and onset-to treatment times. Stroke etiology was classified according to the TOAST classification, with dissection and multiple causes added as categories. Clinical outcome was measured at 3 months with the mRs either in person at the outpatient stroke clinic, or by standardized telephone interview by Rankin-certified medical personnel. Favorable outcome was considered as 3 months mRs  $\leq$  2.

#### **Imaging protocol and analysis**

We assess all individuals with suspected AIS by a multimodal CT scan as part of their standard of care, unless contrast contraindication exists. Non-contrast CT (NCCT) scanning was performed to detect intracranial haemorrhage, hyperdense MCA sign and chronic cerebrovascular lesions (defined as presence of chronic infarct and/or leukoaraiosis≥1 according to Blennow scale). Early ischemic changes in the MCA territory were recorded to calculate ASPECTS.

CTA in helical mode was performed from the aortic arch to the top of the frontal sinuses (120 KV, 150–260 mAs, 0.625 slice-thickness, 50 ml of iodinated contrast at 5 ml/s, delay according to the perfusion data). On CTA, we searched for significant extracranial carotid pathology in the ischemic territory, defined as the presence of  $\geq$  50% stenosis, occlusion, dissection or floating thrombus. Significant intracranial pathology, i.e.  $\geq$  50% stenosis or occlusion, was grouped as proximal if it involved carotid siphon, proximal M1 (i.e. less than 10 mm from M1 origin) or A1 segment, and distal if it involved distal M1, M2, M3 or A2 segment. We calculated clot burden score (CBS) as indicator of clot extension. The collateral score was visually determined from CTA maximal intensity projection

reconstructions and graded according to Tan et al. [\[11\]](#page-6-4) Absence of collateral flow to the ischemic territory was graded as 0, whereas collateral flow in  $\leq 50\%$ , > 50% and  $\geq$  100% of the vessels filling in the ischemic territory distal to the occluded artery was graded as 1 (poor collaterals), 2 (moderate collaterals), and 3 (good collaterals), respectively. Interrater agreement for collateral grading 0–1 vs. 2–3 was evaluated on 100 consecutive patient's proximal intracranial occlusions using Cohen's kappa.

#### **Statistical analysis**

We first performed a univariate analysis (UVA) between demographic, clinical, metabolic and radiological variables depending on collateral status. All grades of collaterals, considered as ordinal categorical variable (0–3), were considered for the primary outcome of the study.

All variables from the UVA, independently from their statistical significance in univariate comparisons, were then used to fit three multivariate logistic models to determine the independent associations with better degrees of collateralization. First, we performed a clinical multivariate analysis (MVA-A) using only demographic, clinical and laboratory variables available before the acquisition of CTA, to provide clinicians with indicators of patients likely to have good collaterals. Second, we analyzed the radiological variables that are independently associated with better collaterals (MVA-B), to provide radiologists with additional information about NCCT variables capable to predict good collaterals. Third, we combined the variables from the two above mentioned models and used all demographic, clinical, metabolic and radiological variables in a comprehensive MVA (MVA-C). This comprehensive analysis aimed to show the most powerful (clinical or radiological) associations, and better understand the pathophysiology of good collaterals.

All analyses were performed using the proportional odds approach. In all MVA analyses, imputation of missing values was carried out using multiple chain equations methodology [[12\]](#page-6-5). In this way, we generated five complete datasets. Analysis of each dataset was performed separately. We used backward elimination techniques to report only covariates significantly associated with the outcome, listed in Table [2.](#page-4-0) The reported results were obtained by appropriately combining the results of the five imputed analyses. In all analyses, type I errors of 5% to test each regression coefficients separately were used. The R package (R version 3.4.1) was used throughout.

Given that the 3 months clinical outcome was considered a secondary, ancillary result, no adjustment was done for this analysis.



<span id="page-2-0"></span>**Fig. 1** Correlation between ASPECTS score and collaterals (ordinal)

## **Results**

Among 2027 patients with AIS involving MCA territory and with good quality acute CTA during the study period, 857 met the inclusion criteria (Suppl. Fig. 1S). Median age was 72.3 (interquartile range, IQR 20.5) years, 415 (48.4%) were females and median admission NIHSS was 16 (IQR 9). Median onset to CT time was 2.5 (IQR 3.4) h. CTA showed M1 occlusion in 620 (72.3%) and proximal M2 occlusion in 237 (27.7%) patients. Collaterals were graded as absent (grade 0) in 77 (9.0%), poor (grade 1) in 345 (40.3%), moderate (grade 2) in 307 (35.8%) and good (grade 3) in 128 (14.9%) patients. Interrater agreement for collateral grading 0–1 vs. 2–3 was 0.81.

Table [1](#page-3-0) shows patient characteristics, laboratory and radiological findings of the study population as well as the results of the univariate analysis (Suppl. Tables 1S and 2S, are extended versions of Table [1](#page-3-0)). The distribution of vascular risk factors was similar among the collateral scores.

Significant results from the MVAs are shown in Table [2.](#page-4-0) In the clinical MVA (MVA-A), better collaterals were associated with lower age (OR 0.99, confidence intervals: see Table [2\)](#page-4-0), lower NIHSS on admission (OR 0.94, see also Suppl. Fig. 2S) and lower frequency of visual field defects (OR 0.70), eye deviation (OR 0.66) and decreased vigilance (OR 0.60). Better collaterals were also associated with nonsmoking status (OR 0.72) and decreased delay to imaging (OR 0.97). When limiting the MVA to radiological variables (MVA-B), better collaterals were associated with a higher ASPECTS score (OR 1.27), higher CBS (OR 1.15), and absence of chronic cerebrovascular lesions (OR 0.72).

Combining all data in a comprehensive MVA (MVA-C), better collaterals were associated with lower age (OR 0.99), hemineglect (OR 1.35), absence of visual field defects (OR 0.64), eye deviation (OR 0.58) and decreased vigilance (OR 0.62). Better collaterals were also associated with dyslipidemia (OR 1.57), absence of statin use (OR 0.96) and lower creatinine levels (OR 0.99). Moreover, we confirmed the positive association between better

<span id="page-3-0"></span>**Table 1** Patient characteristics, laboratory and radiological findings in the study population

Baseline variable and follow-up as median $\pm$ IQR or <i>n</i> (%)	Total pt $(N=857)$	OR	95% CI	
Age (years)	72.3 (20.5)	$0.99*$	$0.98 - 1.00$	
Sex (females)	415/857 (48.4%)	1.08	$0.84 - 1.38$	
<b>Admission NIHSS</b>	16.0(9.0)	$0.91*$	$0.89 - 0.92$	
New neurological deficit				
Visual field defects	619/836 (74.0%)	$0.34*$	$0.25 - 0.46$	
Eye deviation	477/835 (57.1%)	$0.35*$	$0.27 - 0.46$	
Aphasia	435/842 (51.7%)	1.04	$0.81 - 1.33$	
Neglect	431/835 (51.6%)	0.89	$0.69 - 1.14$	
Vigilance impairment	163/836 (19.5%)	$0.34*$	$0.25 - 0.48$	
Premorbid risk factors				
Hypertension	537/852 (63.0%)	0.88	$0.68 - 1.14$	
Diabetes	134/852 (15.7%)	0.85	$0.61 - 1.19$	
Hyperlipidemia	581/851 (68.3%)	1.20	$0.92 - 1.57$	
Current smoking	206/841 (24.5%)	0.87	$0.65 - 1.17$	
Atrial fibrillation	351/854 (41.1%)	0.78	$0.61 - 1.01$	
Pre-stroke $mRS > 2$	68/850 (8.0%)	0.89	$0.57 - 1.40$	
Statin use before stroke	215/846 (25.4%)	0.75	$0.57 - 1.00$	
Laboratory studies				
Blood glucose (mmol/L)	6.7(2.0)	$0.93*$	$0.88 - 0.98$	
Serum creatinine (mg/dL)	87.0 (29.0)	$0.99*$	$0.99 - 1.00$	
Total cholesterol (mmol/L)	5.1(1.6)	1.01	$0.99 - 1.03$	
Onset to CT time (h)	2.5(3.4)	0.98	$0.95 - 1.01$	
Neuroimaging data				
<b>ASPECTS</b> score	8.0(4.0)	$1.32*$	$1.25 - 1.39$	
Significant leukoaraiosis	212/857 (24.7%)	0.84	$0.63 - 1.11$	
Hyperdense MCA sign	398/857 (46.4%)	$0.54*$	$0.42 - 0.70$	
Clot burden score	6.0(4.0)	$1.22*$	$1.16 - 1.27$	
Significant extracranial carotid pathology				
Significant stenosis	69/856 (8.1%)	0.73	$0.46 - 1.16$	
Any occlusion	184/856 (21.5%)	$0.59*$	$0.43 - 0.81$	
TOAST mechanism <sup>†</sup>				
Atherosclerosis	114/828 (13.8%)	0.81	$0.56 - 1.19$	
Cardiac	396/828 (47.8%)			
mRS at 3 months				
$0 - 2$	308/760 (40.5%)	$0.35*$		$0.26 - 0.46$

Odds ratios (OR) with confidence intervals (95% CI) from the univariate analysis of better vs. poorer collaterals are given, with collaterals used as an ordinal variable quantified by four grades

\*Asterisks denote significant findings

† Reference: atherosclerosis

collaterals and higher ASPECTS (OR 1.27 and Fig. [1\)](#page-2-0) and higher CBS (OR 1.09 and Fig. [2](#page-4-1)), respectively.

# **Discussion**

As an ancillary result, we found in unadjusted analysis that a better collateral status was associated with favorable clinical outcome at 3 months (Table [1](#page-3-0)).

In this largest retrospective study of collaterals so far, we investigated factors that are associated to their variability

<span id="page-4-0"></span>**Table 2** Results of the pre-imaging multivariate analysis (MVA-A), the imaging-only MVA (MVA-B), and the comprehensive MVAs (MVA-C)

	<b>OR</b>	95% CI	<i>p</i> value
MVA-A (clinical variable)			
Age	0.99	$0.98 - 1.00$	< 0.01
<b>Admission NIHSS</b>	0.94	$0.92 - 0.97$	< 0.01
Visual field defects	0.70	$0.49 - 1.00$	0.04
Eye deviation	0.66	$0.48 - 0.91$	0.01
Vigilance impairement	0.60	$0.41 - 0.86$	< 0.01
Current smoking	0.72	$0.53 - 0.98$	0.04
Onset to CT time (h)	0.97	$0.94 - 1.00$	0.03
MVA-B (radiological variable)			
<b>ASPECTS</b> score	1.27	$1.20 - 1.34$	< 0.01
Clot burden score	1.15	$1.09 - 1.20$	< 0.01
Chronic cerebrovascular lesions	0.72	$0.54 - 0.96$	0.03
MVA-C (variable)			
Age	0.99	$0.98 - 1.00$	< 0.01
Visual field defects	0.64	$0.46 - 0.90$	< 0.01
Eye deviation	0.58	$0.43 - 0.79$	< 0.01
Neglect	1.35	$1.03 - 1.76$	0.03
Vigilance impairment	0.62	$0.44 - 0.88$	< 0.01
Statin use	0.69	$0.50 - 0.95$	0.02
Hyperlipidemia	1.57	$1.16 - 2.13$	< 0.01
Serum creatinine	0.99	$0.99 - 1.00$	< 0.01
<b>ASPECTS</b> score	1.27	$1.20 - 1.35$	< 0.01
Clot burden score	1.09	$1.03 - 1.14$	< 0.01

Only significant associations are shown



<span id="page-4-1"></span>**Fig. 2** Correlation between Clot Burden Score and collaterals (ordinal)

in patients with AIS and proximal MCA occlusion. We found that favorable collateral patterns could be predicted by lower age, non-smoking status, no previous statin use, dyslipidemia and lower serum creatinine. Better collaterals were more frequently observed in patients with shorter delay to imaging and absence of chronic cerebrovascular lesions. Moreover, better collaterals were associated with lower stroke severity, lower frequency of cortical signs (except for hemineglect), higher ASPECTS and lower clot burden.

The association between younger age and better collateral score is in agreement with previous findings [[8,](#page-6-1) [9](#page-6-2)]. It has been proposed that aging leads to 'collateral rarefaction', a process causing reduction in collateral density and diameter, probably mediated by prolonged endothelial dysfunction [[13\]](#page-6-6). Among vascular risk factors, current smoking was an independent predictor of poorer collaterals in our clinical analysis. The role of smoking in the impairment of collateral extent in the coronary and peripheral bed is well known [[14](#page-6-7)], but studies examining its association with leptomeningeal collateral status in humans are lacking. To the best of our knowledge, there have been no previous reports noting that renal impairment was associated with poor cerebral collaterals. However, hyperuricemia, known to be related to chronic kidney disease, and the presence of metabolic syndrome, have recently been associated with worse collaterals [[8](#page-6-1)]. These findings allow us to generate hypotheses with regard to underlying pathophysiology of collateral formation. Aging, smoking and impaired renal function could reduce collateral extent by either causing endothelial dysfunction or decreasing dilatatory capacity of the pial arteries [[15\]](#page-6-8).

Somewhat unexpectedly, known or newly diagnosed dyslipidemia was associated with better and statin use with poorer collaterals. Previous reports on coronary artery disease demonstrated a positive association of hypercholesterolemia and collateral extension, probably mediated by elevated levels of vascular endothelial growth factor [\[16](#page-6-9)]. Regarding statin use, our findings may be viewed as contradictory and not consistent with previous studies suggesting a role for statins in the promotion of arteriogenesis  $[6, 6]$  $[6, 6]$  $[6, 6]$ [17](#page-6-10)]. In our study, it seems that untreated (newly diagnosed) hyperlipidemia may be a major promoter of collaterogenesis, rather than known and treated hyperlipidemia (i.e. statine use).

A shorter delay from symptoms onset to baseline imaging was independently associated with better collaterals, supporting the concept of time-dependent 'collateral-failure' [\[18](#page-6-11), [19](#page-6-12)]. In the purely radiological analysis, absence chronic infarcts and leukoaraiosis were associated with better collaterals. Leukoaraiosis might be associated with increased arterial stiffness, which lead to less recruitment of collaterals in the acute phase of occlusive ischemic stroke [\[20](#page-6-13)].

In our study, lower rate of cortical signs (i.e. eye deviation and visual field defects) were associated with better collaterals. This is consistent with the anatomical observation that leptomeningeal collaterals mainly supply cortical peripheral areas, whereas deeper structures are predominantly supplied by perforating arteries [[21\]](#page-6-14). Only hemineglect did not fit this pattern, possibly indicating that the critical site of temporal damage responsible for hemineglect is mostly supplied by non-anastomosing arterial systems [[22\]](#page-6-15). The positive association with higher ASPECTS suggests that a higher degree of collaterals may prevent infarct growth [\[19](#page-6-12)]. Moreover, higher clot burden may obstruct more orifices of arteries that could provide collateral blood flow. Inversely, one could hypothesize that collaterals may influence clot length, because patients with poor collaterals may have an increased degree of stasis around the clot and this could lead to a clot extension [\[23](#page-6-16)].

The association of collateral status with clinical outcome was not a main goal of our study. Still, the fact that patients with good collaterals showed a better outcome in unadjusted analysis stresses the need to adjust for this variable when reporting outcomes after revascularization treatments.

The limitations of our study include its retrospective design and its single center nature. In addition, collaterals were estimated semi-quantitatively and CTA-based collateral assessment may be less precise than invasive contrast angiography. Moreover, the use of single-phase CTA may lead to technique-dependency bias in collaterals evaluation due to variability in the timing of the contrast injection and image acquisition.

# **Conclusions**

Our study showed that younger age, non-smoking status, dyslipidemia and lower serum creatinine were predictors of better collaterals in patients with AIS and proximal MCA occlusion. The implications of our findings are several: first, they may add to our understanding of collaterals variability at baseline, indicating that risk factors for diffuse vascular pathology (i.e. smoking, aging, renal function impairment) may play a detrimental role in the development and recruitment of such anastomoses. Conversely, dyslipidemia may exhibit a promoting effect upon angiogenesis. Second, our data suggest that manipulation of physiological parameters such as blood pressure or sugar may not result in better collateral flow, but the latter seems to be largely determined by non-modifiable factors in the acute phase of stroke. Third, the associations between collateral status and ASPECTS, clot burden, and frequent cortical signs suggest that these elements are related and partly interchangeable, measuring similar aspects of the ischemic pathophysiology. These characteristics could be used to identify patients with better collaterals for more aggressive revascularization treatment, even at later timepoints.

**Acknowledgements** We thank Melanie Price Hirt for English language correction and editing. We thank Dr Federico Ricciardi from University College London for helpful suggestions on this manuscript.

**Author contributions** SN studied the concept and design, helped in analysis and interpretation, and preparation of the article. GS, CWC and DS helped in interpretation of data and critical revision of the article for important intellectual content. DL carried out data analysis and interpretation and helped in preparation of the article. AE helped in data acquisition and analysis. PJM helped in radiological data acquisition and critical revision of the article for important intellectual content. MW contributed to the conception and design, and helped in the interpretation of radiological data. PM studied the concept and design, and helped in data acquisition, analysis and interpretation, critical revision of the article for important intellectual content, study supervision.

**Funding** This project was supported by the European Academy of Neurology and the Swiss Heart Foundation.

#### **Compliance with ethical standards**

**Conflicts of interest** In the last 3 years, Prof. P. Michel received research grants from the Swiss Heart Foundation, Boehringer Ingelheim and BMS through his institution; speaker fees from Boehringer Ingelheim, Bayer, Daiichi Sankyo, Medtronic and Amgen; honoraria from scientific advisory boards from Boehringer Ingelheim, Bayer, Pfizer and BMS and consulting fees from Medtronic, Astra-Zeneca and Amgen. His institution (CHUV), receives all of the support for stroke education and research. Dr. G. Sirimarco served on scientific advisory boards for Amgen and Daiichi Sankyo. Dr. C.W. Cereda received research grants from the Swiss Heart Foundation, Advisory Board of Research (EOC) and Boehringer Ingelheim in the last 3 years through his institution; honoraria from scientific advisory boards from Boehringer Ingelheim, Bayer and Pfizer. The other authors report no conflicts of interest.

**Ethical standards** Collection, analysis and publication of data in ASTRAL was approved by the institution's ethical commission.

# **References**

- <span id="page-5-0"></span>1. Liebeskind DS (2003) Collateral circulation. Stroke 34(9):2279– 2284. <https://doi.org/10.1161/01.STR.0000086465.41263.06>
- <span id="page-5-1"></span>2. Vagal A, Menon BK, Foster LD, Livorine A, Yeatts SD, Qazi E, d'Esterre C, Shi J, Demchuk AM, Hill MD, Liebeskind DS, Tomsick T, Goyal M (2016) Association Between CT angiogram collaterals and CT perfusion in the interventional management of stroke III trial. Stroke 47(2):535–538. [https://doi.org/10.1161/](https://doi.org/10.1161/STROKEAHA.115.011461) [STROKEAHA.115.011461](https://doi.org/10.1161/STROKEAHA.115.011461)
- <span id="page-5-2"></span>3. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, Lee KH, Liebeskind DS (2011) Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke 42(3):693–699. [https://doi.org/10.1161/STROKEAHA.110.59525](https://doi.org/10.1161/STROKEAHA.110.595256) [6](https://doi.org/10.1161/STROKEAHA.110.595256)
- <span id="page-5-3"></span>4. Miteff F, Levi CR, Bateman GA, Spratt N, McElduff P, Parsons MW (2009) The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 132(Pt 8):2231–2238. [https://doi.org/10.1093/brain](https://doi.org/10.1093/brain/awp155) [/awp155](https://doi.org/10.1093/brain/awp155)
- <span id="page-5-4"></span>5. Menon BK, Qazi E, Nambiar V, Foster LD, Yeatts SD, Liebeskind D, Jovin TG, Goyal M, Hill MD, Tomsick TA, Broderick JP, Demchuk AM, Interventional Management of Stroke IIII (2015) Differential effect of baseline computed tomographic angiography collaterals on clinical outcome in patients enrolled in the interventional management of stroke III trial. Stroke 46(5):1239–1244. <https://doi.org/10.1161/STROKEAHA.115.009009>
- <span id="page-5-5"></span>6. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, Duckwiler GR, Vinuela F, Pineda S, Liebeskind DS (2007)

Statin enhancement of collateralization in acute stroke. Neurology 68(24):2129–2131. [https://doi.org/10.1212/01.wnl.0000264931](https://doi.org/10.1212/01.wnl.0000264931.34941.f0) [.34941.f0](https://doi.org/10.1212/01.wnl.0000264931.34941.f0)

- <span id="page-6-0"></span>7. Lima FO, Furie KL, Silva GS, Lev MH, Camargo EC, Singhal AB, Harris GJ, Halpern EF, Koroshetz WJ, Smith WS, Yoo AJ, Nogueira RG (2010) The pattern of leptomeningeal collaterals on CT angiography is a strong predictor of long-term functional outcome in stroke patients with large vessel intracranial occlusion. Stroke 41(10):2316–2322. [https://doi.org/10.1161/STROK](https://doi.org/10.1161/STROKEAHA.110.592303) [EAHA.110.592303](https://doi.org/10.1161/STROKEAHA.110.592303)
- <span id="page-6-1"></span>8. Menon BK, Smith EE, Coutts SB, Welsh DG, Faber JE, Goyal M, Hill MD, Demchuk AM, Damani Z, Cho KH, Chang HW, Hong JH, Sohn SI (2013) Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol 74(2):241–248. <https://doi.org/10.1002/ana.23906>
- <span id="page-6-2"></span>9. Malik N, Hou Q, Vagal A, Patrie J, Xin W, Michel P, Eskandari A, Jovin T, Wintermark M (2014) Demographic and clinical predictors of leptomeningeal collaterals in stroke patients. J Stroke Cerebrovasc Dis 23(8):2018–2022. [https://doi.org/10.1016/j.jstro](https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.018) [kecerebrovasdis.2014.02.018](https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.02.018)
- <span id="page-6-3"></span>10. Michel P, Odier C, Rutgers M, Reichhart M, Maeder P, Meuli R, Wintermark M, Maghraoui A, Faouzi M, Croquelois A, Ntaios G (2010) The Acute STroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. Stroke 41(11):2491– 2498.<https://doi.org/10.1161/STROKEAHA.110.596189>
- <span id="page-6-4"></span>11. Tan JC, Dillon WP, Liu S, Adler F, Smith WS, Wintermark M (2007) Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol 61(6):533–543. [https](https://doi.org/10.1002/ana.21130) [://doi.org/10.1002/ana.21130](https://doi.org/10.1002/ana.21130)
- <span id="page-6-5"></span>12. Stef van Buuren KG-O (2011) Multivariate imputation by chained equations in R. J Stat Softw 45(3):1–68
- <span id="page-6-6"></span>13. Faber JE, Zhang H, Lassance-Soares RM, Prabhakar P, Najafi AH, Burnett MS, Epstein SE (2011) Aging causes collateral rarefaction and increased severity of ischemic injury in multiple tissues. Arterioscler Thromb Vasc Biol 31(8):1748–1756. [https://doi.](https://doi.org/10.1161/ATVBAHA.111.227314) [org/10.1161/ATVBAHA.111.227314](https://doi.org/10.1161/ATVBAHA.111.227314)
- <span id="page-6-7"></span>14. Kinnaird T, Stabile E, Zbinden S, Burnett MS, Epstein SE (2008) Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. Cardiovasc Res 78(2):257–264.<https://doi.org/10.1093/cvr/cvm116>
- <span id="page-6-8"></span>15. Moore SM, Zhang H, Maeda N, Doerschuk CM, Faber JE (2015) Cardiovascular risk factors cause premature rarefaction of the

collateral circulation and greater ischemic tissue injury. Angiogenesis 18(3):265–281.<https://doi.org/10.1007/s10456-015-9465-6>

- <span id="page-6-9"></span>16. Kornowski R (2003) Collateral formation and clinical variables in obstructive coronary artery disease: the influence of hypercholesterolemia and diabetes mellitus. Coron Artery Dis 14(1):61–64. <https://doi.org/10.1097/01.mca.0000053970.64840.cd>
- <span id="page-6-10"></span>17. Lee MJ, Bang OY, Kim SJ, Kim GM, Chung CS, Lee KH, Ovbiagele B, Liebeskind DS, Saver JL (2014) Role of statin in atrial fibrillation-related stroke: an angiographic study for collateral flow. Cerebrovasc Dis 37(2):77–84. [https://doi.org/10.1159/00035](https://doi.org/10.1159/000356114) [6114](https://doi.org/10.1159/000356114)
- <span id="page-6-11"></span>18. Cheripelli BK, Huang X, McVerry F, Muir KW (2016) What is the relationship among penumbra volume, collaterals, and time since onset in the first 6 h after acute ischemic stroke? Int J Stroke 11(3):338–346.<https://doi.org/10.1177/1747493015620807>
- <span id="page-6-12"></span>19. Campbell BC, Christensen S, Tress BM, Churilov L, Desmond PM, Parsons MW, Barber PA, Levi CR, Bladin C, Donnan GA, Davis SM, Investigators E (2013) Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab 33(8):1168–1172. [https://doi.org/10.1038/jcbfm](https://doi.org/10.1038/jcbfm.2013.77) [.2013.77](https://doi.org/10.1038/jcbfm.2013.77)
- <span id="page-6-13"></span>20. Turk M, Zaletel M, Pretnar Oblak J (2016) Characteristics of cerebral hemodynamics in patients with ischemic leukoaraiosis and new ultrasound indices of ischemic leukoaraiosis. J Stroke Cerebrovasc Dis 25(4):977–984. [https://doi.org/10.1016/j.jstrokecer](https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.045) [ebrovasdis.2015.12.045](https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.12.045)
- <span id="page-6-14"></span>21. Menon BK, Smith EE, Modi J, Patel SK, Bhatia R, Watson TW, Hill MD, Demchuk AM, Goyal M (2011) Regional leptomeningeal score on CT angiography predicts clinical and imaging outcomes in patients with acute anterior circulation occlusions. AJNR 32(9):1640–1645.<https://doi.org/10.3174/ajnr.A2564>
- <span id="page-6-15"></span>22. Verdon V, Schwartz S, Lovblad KO, Hauert CA, Vuilleumier P (2010) Neuroanatomy of hemispatial neglect and its functional components: a study using voxel-based lesion-symptom mapping. Brain 133(Pt 3):880–894.<https://doi.org/10.1093/brain/awp305>
- <span id="page-6-16"></span>23. Alves HC, Treurniet KM, Dutra BG, Jansen IGH, Boers AMM, Santos EMM, Berkhemer OA, Dippel DWJ, van der Lugt A, van Zwam WH, van Oostenbrugge RJ, Lingsma HF, Roos Y, Yoo AJ, Marquering HA, Majoie C, Investigators MCt (2018) Associations between collateral status and thrombus characteristics and their impact in anterior circulation stroke. Stroke 49(2):391–396. [https](https://doi.org/10.1161/STROKEAHA.117.019509) [://doi.org/10.1161/STROKEAHA.117.019509](https://doi.org/10.1161/STROKEAHA.117.019509)

# **Affiliations**

# StefaniaNannoni<sup>1</sup><sup>®</sup> · Gaia Sirimarco<sup>1</sup> · Carlo W. Cereda<sup>1,2</sup> · Dimitris Lambrou<sup>1</sup> · Davide Strambo<sup>1</sup> · **Ashraf Eskandari1 · Pascal J. Mosimann3 · Max Wintermark4 · Patrik Michel1**

- <sup>1</sup> Stroke Center, Neurology Service, Lausanne University Hospital, Rue du Bugnon, 46, 1011 Lausanne, Switzerland
- Stroke Center, Neurology Service, Neurocenter of Southern Switzerland, Ospedale Civico di Lugano, Lugano, Switzerland
- <sup>3</sup> Neuroradiology Division, Department of Radiology, Inselspital, Bern, Switzerland
- Neuroradiology Division, Department of Radiology, Stanford University and Medical Center, Stanford, USA